Navigation Links
Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
Date:4/28/2009

s. AEs were reported in 70.3% subjects in the NT-201 group and 61.8% subjects in the placebo group. The most commonly reported AEs were eyelid ptosis (18.9 vs. 8.8%), dry eye (16.2 vs. 11.8%), and dry mouth (16.2 vs. 2.9%).

Clinical efficacy in focal dystonia and overall tolerability of NT-201 (botulinum neurotoxin free from complexing proteins) Presented by Susanne Grafe of Merz Pharmaceuticals GmbH, Frankfurt, Germany.

Methods

This study assessed the overall clinical efficacy and tolerability of NT-201 (botulinum neurotoxin free from complexing proteins). Efficacy analyses in focal dystonia were performed on pooled data from 2 pivotal clinical trials in blepharospasm and cervical dystonia (343 NT-201 patients; 340 BoNT patients). For the safety analyses, 6 clinical trials (blepharospasm, cervical dystonia and upper limb spasticity) were included (n=539 NT-201, n=442 BoNT and n=75 placebo subjects, respectively). Spontaneously reported adverse events were analyzed.

Results

In the randomized, active-controlled, double-blind studies in focal dystonia NT-201 and one other Botulinum toxin (BoNT) have been used with a dose ratio of 1:1. The results demonstrate equivalent efficacy between the two products. Onset, waning, and duration of effect were comparable. These findings have been confirmed by the Global Impression of Physician: 70.6% of BoNT patients and in 71.8% of the NT-201 patients were rated as "good" or "very good." A total of 26.7% of patients in the NT-201 group, 26.0% in the BoNT group and 22.7% in the placebo group reported an adverse event. There were no clinically relevant differences between the two treatment groups. All adverse reactions were either already known and/or were considered unlikely to be related to NT-201 by the physician. The analysis of the 67,000 patients treated post-launch dem
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
2. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
3. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
4. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
5. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
6. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
7. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
8. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
9. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
10. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
11. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)...  U.S. pharmacy cost increases for active employees and pre- ... double-digits by 2016, according to an analysis by Aon ... of Aon plc (NYSE: AON ). Pharmacy ... 9.5 percent in 2015 and will continue to rise to ... similar rate of increase in 2017, with pharmacy costs rising ...
(Date:4/20/2015)... SAN DIEGO , April 20, 2015 /PRNewswire/ ... biotechnology company developing novel oncology and drug-delivery therapies, ... at the American Association for Cancer Research (AACR) ... interim results of its randomized Phase 2 study ... the annual meeting of the American Society of ...
(Date:4/20/2015)... , April 20, 2015  OpGen, Inc., a ... expansion of its executive management team with the ... ) executive Kevin Krenitsky , M.D. as ... interim chief financial officer. With ... managing global diagnostic and biotechnology operations, including senior ...
Breaking Medicine Technology:Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 2Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 3Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 4Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 2Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 3Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 4Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 5OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer 2OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer 3OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer 4
... announces that a new market research report is ... Delivery in Central Nervous System Diseases - technologies,markets ... The delivery of drugs to ... the treatment of neurological disorders. Drugs may be ...
... Md., April 29, 2011 Don,t let expired or unused ... them properly to prevent them from harming others. ... the second annual National Prescription Drug Take-Back Day, sponsored by ... View a slideshow and read a Consumer Update from the ...
Cached Medicine Technology:Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 2Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 3Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 4
(Date:4/20/2015)... Burlington, Vt. (PRWEB) April 20, 2015 ... environmental networks, is excited to announce that Kate Williams, the ... CEO, effective May 1, 2015. , Williams has been part ... nearly decade-long tenure as Executive Director of the Northern Forest ... Williams has dedicated her career to the stewardship of and ...
(Date:4/20/2015)... 2015 Today the members of ... Fund-Ovarian Cancer National Alliance-National Ovarian Cancer Coalition Translational ... will focus on “DNA Repair Therapies for Ovarian ... DNA repair as a common weakness in ovarian ... early detection of ovarian cancer by developing a ...
(Date:4/20/2015)... Grateful Dead originally formed in 1965 ... 1995. The group was more than just about rock music. ... space rock, country, and other genres to put together their ... The group was inducted into the Rock and Roll Hall ... than 35 million records worldwide. This year marks the ...
(Date:4/20/2015)... Westchester County, New York (PRWEB) April 20, 2015 ... that the Centers for Medicare & Medicaid Services introduced ... of their HCAHPS (Hospital Consumer Assessment of Healthcare Providers ... This national survey asks patients about their experiences during ... current survey results from July 1, 2013 through June ...
(Date:4/20/2015)... Insuranceautoquote.info has released a new blog post ... online . , Affordable auto insurance quotes can ... should always compare online car insurance rates in their ... website: . http://insuranceautoquote.info , The process is ... in a few minutes and the search engine offers ...
Breaking Medicine News(10 mins):Health News:1% for the Planet Announces New CEO 2Health News:1% for the Planet Announces New CEO 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 2Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 4Health News:Grateful Dead Tickets at Levi’s Stadium in Santa Clara: Ticket Down Slashes Grateful Dead Tickets in Santa Clara @ Levi’s Stadium for "Fare Thee Well" 50th Anniversary 2Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 2Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 3Health News:Affordable Auto Insurance Quotes Can Be Found Online, Fast and Easy 2
... Blue Distinction Centers,for Complex and Rare Cancers(SM), CHICAGO, ... the overall quality of healthcare in America, Blue Cross ... Today, Blue Cross and Blue Shield members have ... Complex and Rare Cancers across 33,states. With this expansion, ...
... Inc. (Nasdaq: ALXN ) today announced that Leonard ... at,two upcoming investor conferences, one sponsored by Cowen and ... will present at the Cowen and Company 27th Annual ... Tuesday, March 18, 2008.,Dr. Bell will also present at ...
... Granite State Manufacturing (GSM),a New Hampshire-based ... acquired Scandia Manufacturing Company Inc. (Scandia),a leading ... systems,for the Department of Defense. The acquisition ... States Navy., Granite State Manufacturing plans ...
... March 11 Pepperdine,University,s Graziadio School of ... to a MBA business plan addressing California,s ... Mara Kamins, Nurse,Education Web, a web-based clinical ... place in the Pepperdine University Fourth Annual,Business ...
... Education at ... ... 11 ,GetWellNetwork, Inc., a leading provider of Interactive Patient Care ... today announced a partnership to co-develop a comprehensive,suite of pediatric ...
... 11 EaglePicher,Medical Power, a leading supplier of ... that Joseph (Joe) Marotta has,joined the company as ... this position, Mr. Marotta will be responsible for ... including customer,development initiatives. EaglePicher,s medical division has seen ...
Cached Medicine News:Health News:Blue Cross and Blue Shield's Blue Distinction(R) Designation Improves Healthcare by Focusing on Quality 2Health News:Blue Cross and Blue Shield's Blue Distinction(R) Designation Improves Healthcare by Focusing on Quality 3Health News:Blue Cross and Blue Shield's Blue Distinction(R) Designation Improves Healthcare by Focusing on Quality 4Health News:Granite State Manufacturing Acquires Scandia Manufacturing Company Inc. 2Health News:Pepperdine Business Plan Competition Awards $26,000 to MBA Teams 2Health News:Pepperdine Business Plan Competition Awards $26,000 to MBA Teams 3Health News:GetWellNetwork and KidsHealth Partner to Empower Pediatric Patients and Their Families 2Health News:GetWellNetwork and KidsHealth Partner to Empower Pediatric Patients and Their Families 3Health News:GetWellNetwork and KidsHealth Partner to Empower Pediatric Patients and Their Families 4Health News:EaglePicher Medical Power Names Joseph Marotta Vice President of Sales and Marketing 2
... The Titan™ Inflatable Penile ... system designed to be surgically ... the management of erectile dysfunction ... implant provides the patient with ...
... The Alpha I continues to be a ... the Alpha I to have mechanical reliability ... on first-time implants. ioflex material contributes to ... I. Thats because Bioflex: ,Provides maximum, controlled ...
... advanced three-part inflatable prosthesis consisting of a reservoir ... the scrotum and a pair of cylinders inserted ... look and performance of a natural erection. The ... AMS 700 Series now features the new Tactile ...
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
Medicine Products: